Departments of Neurological Surgery and.
J Neurosurg. 2014 Mar;120(3):708-15. doi: 10.3171/2013.11.JNS131607. Epub 2013 Dec 13.
To assess the long-term outcomes of stereotactic radiosurgery (SRS) for cerebellopontine angle (CPA) meningiomas, the authors retrospectively reviewed data from a 20-year experience. They evaluated progression-free survival as well as improvement, stabilization, or deterioration in clinical symptoms.
Seventy-four patients with CPA meningiomas underwent SRS involving various Gamma Knife technologies between 1990 and 2010. The most common presenting symptoms were dizziness or disequilibrium, hearing loss, facial sensory dysfunction, and headache. The median tumor volume was 3.0 cm(3) (range 0.3-17.1 cm(3)), and the median radiation dose to the tumor margin was 13 Gy (range 11-16 Gy). The median follow-up period was 40 months (range 4-147 months).
At last imaging follow-up, the tumor volume had decreased in 46 patients (62%), remained stable in 26 patients (35%), and increased in 2 patients (3%). The progression-free survival after SRS was 98% at 1 year, 98% at 3 years, and 95% at 5 years. At the last clinical follow-up, 23 patients (31%) showed neurological improvement, 43 patients (58%) showed no change in symptoms or signs, and 8 patients (11%) had worsening symptoms or signs. The neurological improvement rate after SRS was 16% at 1 year, 31% at 3 years, and 40% at 5 years. The post-SRS deterioration rate was 5% at 1 year, 10% at 3 years, and 16% at 5 years. A multivariate analysis demonstrated that trigeminal neuralgia was the symptom most likely to worsen after SRS (HR 0.08, 95% CI 0.02-0.31; p = 0.001). Asymptomatic peritumoral edema occurred in 4 patients (5%) after SRS, and symptomatic adverse radiation effects developed in 7 patients (9%).
Stereotactic radiosurgery for CPA meningiomas provided a high tumor control rate and relatively low risk of ARE. Tumor compression of the trigeminal nerve by a CPA meningioma resulted in an increased rate of facial pain worsening in this patient experience.
评估立体定向放射外科(SRS)治疗桥小脑角(CPA)脑膜瘤的长期疗效,作者回顾性分析了 20 年的经验数据。他们评估了无进展生存率以及临床症状的改善、稳定或恶化。
1990 年至 2010 年间,74 例 CPA 脑膜瘤患者采用各种伽玛刀技术行 SRS 治疗。最常见的首发症状为头晕或失衡、听力损失、面部感觉功能障碍和头痛。肿瘤体积中位数为 3.0cm3(范围 0.3-17.1cm3),肿瘤边缘的中位放射剂量为 13Gy(范围 11-16Gy)。中位随访时间为 40 个月(范围 4-147 个月)。
末次影像学随访时,46 例(62%)患者肿瘤体积缩小,26 例(35%)患者肿瘤体积稳定,2 例(3%)患者肿瘤体积增大。SRS 后 1 年、3 年和 5 年无进展生存率分别为 98%、98%和 95%。末次临床随访时,23 例(31%)患者神经功能改善,43 例(58%)患者症状或体征无变化,8 例(11%)患者症状或体征恶化。SRS 后 1 年、3 年和 5 年的神经改善率分别为 16%、31%和 40%。SRS 后恶化率分别为 5%、10%和 16%。多因素分析显示,SRS 后最有可能恶化的症状是三叉神经痛(HR 0.08,95%CI 0.02-0.31;p = 0.001)。SRS 后 4 例(5%)患者出现无症状性瘤周水肿,7 例(9%)患者出现症状性放射性不良反应。
SRS 治疗 CPA 脑膜瘤肿瘤控制率高,放射性不良反应风险相对较低。CPA 脑膜瘤压迫三叉神经导致患者面部疼痛恶化的发生率增加。